UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2016
Cynapsus Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Canada | 001-37426 | 98-1226819 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
828 Richmond Street West, Toronto, Ontario, Canada (Address of principal executive offices) |
M6J 1C9 (Zip Code) |
Registrant’s telephone number, including area code: 416-703-2449
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On August 15, 2016, Cynapsus Therapeutics Inc. (the “Company”) issued a press release announcing that the Data Safety and Monitoring Board (“DSMB”) has completed a review of early safety data from the Company’s Phase 3 program for APL-130277, including CTH-300 and CTH-301 clinical trials. As a result of the DSMB’s review, the six-month open label CTH-301 study will be amended to allow for at-home titration, after the patient’s initial visit to the clinic. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
d) Exhibits
The following exhibit is filed herewith:
Exhibit | Description | |
99.1 | Press release dated August 15, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CYNAPSUS THERAPEUTICS INC. | ||
Date: August 15, 2016 | By: | /s/ Andrew Williams |
Name: | Andrew Williams | |
Title: | Chief Operating Officer and | |
Chief Financial Officer |
EXHIBIT INDEX
Exhibit | Description | |
99.1 | Press release dated August 15, 2016. |